Literature DB >> 2226498

Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins.

A King1, C Boothman, I Phillips.   

Abstract

In in vitro tests the broad-spectrum cephalosporins cefpirome and cefepime were highly active against Enterobacteriaceae, although often less so against strains resistant to amoxicillin-clavulanate and ticarcillin-clavulanate, and against most strains of Acinetobacter spp. and Aeromonas hydrophila. They were also active against Pseudomonas aeruginosa, although strains with non-plasmid mediated beta-lactam resistance were sometimes less sensitive. Other Pseudomonas spp. varied in their sensitivity. Both agents were highly active against Haemophilus influenzae, but beta-lactamase-producing Branhamella catarrhalis were somewhat less sensitive. Neisseria gonorrhoeae were susceptible, although non-beta-lactamase producing penicillin-resistant strains had higher MICs. Gardnerella vaginalis was also susceptible and Campylobacter coli/jejuni usually susceptible. Both antibiotics had good activity against Staphylococcus aureus and coagulase-negative staphylococci except for methicillin-resistant strains and Staphylococcus haemolyticus which were of borderline sensitivity. All streptococci were sensitive, with the exception of highly penicillin-resistant pneumococci and enterococci against which cefpirome had greater activity than cefepime. Both antibiotics had little useful activity against the Bacteroides fragilis group or Bacteroides oralis group but were active against most other anaerobes. Clostridium difficile and some other Clostridium species were resistant.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2226498     DOI: 10.1007/bf01964272

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  5 in total

1.  Breakpoints in in-vitro antibiotic sensitivity testing. Report by a working party of the British Society for Antimicrobial Chemotherapy.

Authors: 
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

2.  The in vitro antibacterial activity of cefotaxime compared with that of cefuroxime and cefoxitin.

Authors:  A King; C Warren; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

3.  In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.

Authors:  R N Jones; C Thornsberry; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

4.  The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

5.  Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.

Authors:  R E Kessler; M Bies; R E Buck; D R Chisholm; T A Pursiano; Y H Tsai; M Misiek; K E Price; F Leitner
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

  5 in total
  11 in total

Review 1.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 2.  Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.

Authors:  L R Wiseman; H M Lamb
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

3.  Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.

Authors:  J Martínez-Beltrán; R Cantón; J Liñares; J García de Lomas; C Gimeno; F Tubau; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

Review 4.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 5.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

Review 6.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

7.  Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment.

Authors:  J Cronqvist; I Nilsson-Ehle; B Oqvist; S R Norrby
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 8.  Gardnerella vaginalis: characteristics, clinical considerations, and controversies.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

Review 9.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 10.  Update on clinical significance of coagulase-negative staphylococci.

Authors:  W E Kloos; T L Bannerman
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.